雷迪帕韦/索磷布韦联合或不联合利巴韦林治疗8周或12周用于治疗HCV基因4型感染:埃及随机III期研究结果
这项在埃及四中心开展的开放标签III期随机研究纳入255例HCV基因4型患者,初治者随机接受8周或12周雷迪帕韦/索磷布韦联合或不联合利巴韦林,经治者接受12周方案。初治患者8周联合利巴韦林方案SVR12为90%,8周单药为95%,12周单药及联合利巴韦林均为98%;干扰素经治者12周单药SVR12为94%,联合利巴韦林为100%;既往索磷布韦方案治疗失败者联合利巴韦林均获SVR12。
要点
- 初治无肝硬化患者8周雷迪帕韦/索磷布韦联合或不联合利巴韦林高度有效。
- 12周方案无论是否存在肝硬化或既往治疗史(含索磷布韦方案)均高度有效。
- 头痛和乏力是最常见不良事件,在接受利巴韦林的患者中更常见。
核心结论
- 在无肝硬化的HCV基因4型初治患者中,8周雷迪帕韦/索磷布韦联合或不联合利巴韦林高度有效。
- 12周雷迪帕韦/索磷布韦联合或不联合利巴韦林无论是否存在肝硬化或既往治疗经验(包括既往索磷布韦或雷迪帕韦/索磷布韦治疗)均高度有效。
研究设计与样本
- 开放标签、多中心、III期研究,纳入埃及四个中心的255例HCV基因4型患者。
- 初治患者随机接受8周或12周雷迪帕韦/索磷布韦联合或不联合利巴韦林。
- 干扰素经治患者随机接受12周雷迪帕韦/索磷布韦联合或不联合利巴韦林。
- 索磷布韦经治或雷迪帕韦/索磷布韦经治患者接受12周雷迪帕韦/索磷布韦联合利巴韦林。
- 随机化按肝硬化状态分层,主要终点为治疗结束后12周持续病毒学应答(SVR12)。
主要发现
- 初治患者中,8周雷迪帕韦/索磷布韦单药SVR12为95%,联合利巴韦林为90%;12周单药及联合利巴韦林均为98%。
- 干扰素经治患者中,12周雷迪帕韦/索磷布韦单药SVR12为94%,联合利巴韦林为100%。
- 所有既往接受索磷布韦方案治疗并接受雷迪帕韦/索磷布韦联合利巴韦林的患者均获得SVR12。
- 最常见不良事件为头痛和乏力,在接受利巴韦林的患者中更常见。
关键数值与推荐
- 初治患者8周雷迪帕韦/索磷布韦单药SVR12为95%,联合利巴韦林为90%。
- 初治患者12周雷迪帕韦/索磷布韦单药及联合利巴韦林SVR12均为98%。
- 干扰素经治患者12周雷迪帕韦/索磷布韦单药SVR12为94%,联合利巴韦林为100%。
- 既往索磷布韦方案经治患者接受12周雷迪帕韦/索磷布韦联合利巴韦林均获得SVR12。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We evaluated the efficacy and safety of ledipasvir/sofosbuvir alone and with ribavirin for 8 and 12 weeks in Egyptian patients with and without cirrhosis, who were infected with hepatitis C virus (HCV) genotype 4, including those who had failed previous treatment with sofosbuvir regimens. DESIGN: In this open-label, multicentre, phase III study, treatment-naive patients were randomised to receive 8 or 12 weeks of ledipasvir/sofosbuvir±ribavirin. Interferon treatment-experienced patients were randomised to receive 12 weeks of ledipasvir/sofosbuvir±ribavirin, while sofosbuvir-experienced or ledipasvir/sofosbuvir-experienced patients received 12 weeks of ledipasvir/sofosbuvir+ribavirin. Randomisation was stratified by cirrhosis status. The primary endpoint was sustained virological response 12 weeks post-treatment (SVR12). RESULTS: We enrolled 255 patients from four centres in Egypt. Among treatment-naive patients, SVR12 rates were 95% and 90% for those receiving 8 weeks of ledipasvir/sofosbuvir alone and with ribavirin, respectively, and 98% for those receiving 12 weeks of ledipasvir/sofosbuvir both alone and with ribavirin. Among interferon-experienced patients, SVR rates were 94% for those receiving 12 weeks of ledipasvir/sofosbuvir and 100% for those receiving 12 weeks of ledipasvir/sofosbuvir plus ribavirin. All patients previously treated with sofosbuvir regimens who received ledipasvir/sofosbuvir plus ribavirin achieved SVR12. The most common adverse events, headache and fatigue, were more common among patients receiving ribavirin. CONCLUSION: Among non-cirrhotic treatment-naive patients with HCV genotype 4, 8 weeks of ledipasvir/sofosbuvir±ribavirin was highly effective. Twelve weeks of ledipasvir/sofosbuvir±ribavirin was highly effective regardless of presence of cirrhosis or prior treatment experience, including previous treatment with sofosbuvir or ledipasvir/sofosbuvir. TRIAL REGISTRATION NUMBER: NCT02487030.
引用
- Shiha G, Esmat G, Hassany M, et al. Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. Gut. 2018. PMID: 29666174. doi:10.1136/gutjnl-2017-315906
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。